Results 21 to 30 of about 56,482 (307)

Proton beam therapy in paediatric cancer: Anticipating the opening of the Australian Bragg Centre for Proton Therapy and Research

Journal of Medical Imaging and Radiation Oncology, EarlyView., 2023
Summary Proton Beam Therapy (PBT) has the potential to improve paediatric cancer care by reducing radiation exposure and thus long‐term toxicities. Ethical concerns and debates surrounding the treatment, such as eligibility and accessibility, are ongoing in Australia. The Australian Bragg Centre for Proton Therapy and Research (ABCPTR) (named after Sir
Jeremy Khong, Hui Tee, Peter Gorayski, Hien Le, Michael Penniment, Sophie Jessop, Jordan Hansford, Melanie Penfold, Julia Green, Kelly Skelton, Frank Saran   +10 more
wiley   +1 more source

GANT-61 induces cell cycle resting and autophagy by down-regulating RNAP III signal pathway and tRNA-Gly-CCC synthesis to combate chondrosarcoma

Cell Death and Disease, 2023
Chondrosarcoma is ineffective for conventional radiotherapy and chemotherapy with a poor prognosis. Hedgehog (Hh) signal pathway plays a crucial role in tumor growth and progression, which is constitutive activated in chondrosarcoma.
Yifeng Sun, Qiongxuan Fang, Wei Liu, Yi Liu, Chunming Zhang   +4 more
doaj   +1 more source

Immunotherapy for Chordoma and Chondrosarcoma: Current Evidence

Cancers, 2021
Simple Summary Chordomas and chondrosarcomas are rare tumors that can occur within the skull base and spinal column and are often resistant to chemotherapy and radiation.
Jeffrey I. Traylor, M. Pernik, Aaron R Plitt, Michael Lim, T. Garzon-Muvdi   +4 more
semanticscholar   +1 more source

Enhanced Functional and Surgical Outcomes With 3D Printing in Orthopedic Oncology: A Comparative Meta-Analysis Against Conventional Techniques. [PDF]

J Surg Oncol
ABSTRACT Introduction Three‐dimensional printing (3DP) technology has increasingly gained attention in orthopedic oncology, where complex tumor resections and reconstructions demand high precision. 3DP enables the creation of patient‐specific models and prostheses, which can improve postoperative quality of life for patients while assisting surgeons in
Mounsef PJ, Blackman B, Sharma O, Aoude A, Bozzo A.   +4 more
europepmc   +2 more sources

TERT promoter mutation is an objective clinical marker for disease progression in chondrosarcoma

Modern Pathology, 2021
Chondrosarcomas are the second most common malignant bone tumor. Activating promoter mutations in telomerase reverse transcriptase (TERT) was recently described by us and others as a frequent mutation in high-grade chondrosarcoma.
Yifan Zhang, Yi Chen, Chen Yang, Nelly Seger, A. Hesla, P. Tsagkozis, O. Larsson, Yingbo Lin, F. Haglund   +8 more
semanticscholar   +1 more source

Visfatin Promotes the Metastatic Potential of Chondrosarcoma Cells by Stimulating AP-1-Dependent MMP-2 Production in the MAPK Pathway

International Journal of Molecular Sciences, 2021
Chondrosarcoma is a malignant bone tumor that is characterized by high metastatic potential and marked resistance to radiation and chemotherapy. The knowledge that adipokines facilitate the initiation, progression, metastasis, and treatment resistance of
Shih-Ya Hung, Chih-Yang Lin, Cheng Yu, Hsien-Te Chen, M. Lien, Yu-Wen Huang, Y. Fong, Ju-Fang Liu, Shih-Wei Wang, Wei‐Cheng Chen, Chih-Hsin Tang   +10 more
semanticscholar   +1 more source

Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma.

Journal of Clinical Oncology, 2020
PURPOSE Surgery is the primary therapy for localized chondrosarcoma; for locally advanced and/or metastatic disease, no known effective systemic therapy exists.
W. Tap, V. Villalobos, G. Cote, H. Burris, F. Janku, O. Mir, M. Beeram, A. Wagner, Liewen Jiang, Bin Wu, S. Choe, K. Yen, C. Gliser, Bin Fan, S. Agresta, S. Pandya, J. Trent   +16 more
semanticscholar   +1 more source

Chondroitin sulfate proteoglycan 4 expression in chondrosarcoma: A potential target for antibody-based immunotherapy

Frontiers in Oncology, 2022
Chondrosarcoma is a common primary bone malignancy whose phenotype increases with its histologic grade. They are relatively resistant to chemotherapy and radiation therapy limiting curative options for disseminated disease.
Sjoerd P. F. T. Nota, Sjoerd P. F. T. Nota, Sjoerd P. F. T. Nota, David O. Osei-Hwedieh, David O. Osei-Hwedieh, David L. Drum, Xinhui Wang, Francesco Sabbatino, Soldano Ferrone, Joseph H. Schwab, Joseph H. Schwab   +10 more
doaj   +1 more source

A Macroscopic Mathematical Model For Cell Migration Assays Using A Real-Time Cell Analysis [PDF]

, 2016
Experiments of cell migration and chemotaxis assays have been classically performed in the so-called Boyden Chambers. A recent technology, xCELLigence Real Time Cell Analysis, is now allowing to monitor the cell migration in real time.
Angelini, Claudia, Carfora, Maria Francesca, Carriero, Maria Vincenza, Di Costanzo, Ezio, Ingangi, Vincenzo, Natalini, Roberto   +5 more
core   +7 more sources

Survival and Prognosis of Chondrosarcoma Subtypes: SEER Database Analysis

Journal of Orthopaedic Research, 2020
Chondrosarcomas are rare tumors and, historically, investigation of these tumors has been limited to small series and single‐institution studies. There have been no studies that evaluated the identification or comparison of differences in prognostic ...
Kamil M. Amer, M. Munn, Dominick Conguista, J. Abraham, A. Mallick   +4 more
semanticscholar   +1 more source